Blog Layout
Gestalt Diagnostics Announces Advisory Board Formation with Leading Industry Experts
Gestalt Diagnostics has created an Advisory Board led by their Medical Director, Dr. David Hoak. The board consists of Pathologists who have extensive backgrounds in leading edge technology, regulatory expertise and a focus on emerging technologies such as digital pathology.
Advisory board members include:
Dr. Bruce Beckwith, pathologist and Chairman of Pathology at North Shore Medical Center in Salem, MA with an
appointment in Pathology at Massachusetts General Hospital in Boston, MA. Dr. Beckwith serves as the College of
American Pathologists (CAP) liaison to the DICOM Pathology Working Group (WG-26) and was a founding co-chair of
that group. He has also been a member of multiple informatics related committees of the CAP and is currently a member
of the CAP Digital Pathology committee. In addition to his interests in standards development and pathology imaging,
Dr. Beckwith has collaborated on informatics research projects related to making de-identified pathology data and
archival material available for research using a peer to peer networking architecture. When asked about joining the
Gestalt Diagnostics Advisory Board Dr. Beckwith said “I am very excited to work with the team at Gestalt to help inform
the development of software tools that will make it easier for pathologists to adopt digital pathology.”
Dr. Eric Glassy, a community pathologist in Southern California and director of pathology at Providence Little Company
of Mary Medical Center, San Pedro. He is a member of Affiliated Pathologists Medical Group, a 40 person independent
pathology group covering 15 hospitals and laboratories in California, Portland and Phoenix. Dr. Glassy has won a number
of pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of
American Pathologists (CAP). He has chaired hospital and CAP national committees. He served as chairman of the
Hematology and Clinical Microscopy Resource, Publications, Digital Pathology and Curriculum Committees. He is a past
Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is past president of the
Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software
programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma. He is a trustee
of the American Board of Pathology as well as a board member of the CAP. “I am happy to participate in helping Gestalt
roll out their meaningful and impactful digital pathology solution”, says Dr. Glassy.
Dr. John Spinosa, M.D., Ph.D. is the Chief Medical Officer at the San Diego Blood Bank. Dr. Spinosa has a broad
background in clinical and anatomic pathology, hematology, molecular diagnostics and informatics. He spent 20 years at
Scripps Memorial Hospital as Medical Director, Chief of Staff and Chair of Pathology, and has extensive experience in
hospital-based general surgical pathology. He is also entrepreneurial, serving as CMO/Medical Director of local clinical
laboratories at Lexent Bio, Avera, Trovagene, Verinata Health, Prometheus, Esoterix Oncology and other specialty labs.
Dr. Spinosa says, "I look forward to engaging with Gestalt Diagnostics to help provide useful, functional products for the
practicing pathologist that can facilitate the incorporation of whole slide imaging into routine clinical practice. Providing
improved tools is essential in keeping pathology practice vibrant for health systems, physician clients, and patients."
Dr. David Hoak, Gestalt Medical Director, says, "I am pleased and excited that Drs. Eric Glassy, John Spinosa and Bruce
Beckwith are joining the scientific advisory board of Gestalt Diagnostics. Their expertise in informatics and digital
pathology will help refine and improve Gestalt's digital pathology products that seek to improve pathologists' workflow
and efficiency. "
Gestalt Diagnostics is a private, profit-driven software company who has developed PathFlow, an enterprise software
platform specifically designed to bring the benefits of digital workflow to pathologists and pathology
laboratories. This product was originally developed, by what is now Gestalt’s team, to support a fully digital
reading platform for radiology. The radiology platform is used in leading hospitals across the United States and
supports more than 15 million studies annually. Gestalt has expanded and redesigned this proven, robust
solution to work in the laboratory space – engineered for the unique needs and workflow of pathologists.
Gestalt’s Advisory Board guides the development of Gestalt’s digital pathology platform,
PathFlow® – made by pathologists for pathologists
A Digital Pathology Today podcast with Lisa-Jean Clifford of Gestalt - A Fresh Start for Pathology
Gestalt Diagnostics, Inc., a leading provider of (AI)-driven digital pathology solutions, is proud to announce the launch of its leading-edge AI Algorithm Evaluator. This groundbreaking, patent-pending tool empowers pathologists, researchers, and healthcare professionals to assess and compare the performance of AI algorithms with unprecedented precision directly within our award-winning PathFlow® solution. This new feature will be demonstrated during the USCAP 2024 conference in Baltimore this week.
March 20, 2024 – Spokane, Washington – Gestalt, a leading provider of (AI)-driven digital pathology solutions, is excited to announce a series of significant enhancements to its educational module and digital pathology solution, within the PathFlow® solution. These advancements underscore Gestalt's commitment to transforming healthcare from every perspective. Our newly expanded Education Module now includes automated, digital evaluation, proficiency testing, credentialing management, and results comparison features. Designed to streamline and ease the heavily manual processes of pathologist proficiency testing, onboarding, and credentialing. "Our commitment to innovation extends across all facets of pathology, from Anatomic Pathology (AP), Research, and Education to Management and Administrative functions. These enhancements reflect our vision for a future where education and technology converge to improve operational processes," says Lisa-Jean Clifford, Chief Strategy Officer and COO at Gestalt Diagnostics. "Our solutions are designed to significantly streamline workflow, enhance efficiency, support patient safety, and offer improved quality and cost. We believe that delivering products with these goals in mind will have a major impact on operations within healthcare, academic, and research facilities, for the pathologist, scientist, and clinician, ultimately providing faster, more accurate diagnosis and treatment for the patient and optimized operations with significant savings to organizations." Gestalt Diagnostics has a proven track record of excellence. Its customers are already leveraging the company's expertise for primary diagnoses*, tumor boards, onboarding and training, collaboration, and supporting remote access for hundreds of client pathologists who are geographically dispersed. Additionally, Gestalt supports research and retrospective image and data capture for over 10 million pathology slides. Join us at USCAP, March 23-28, at booth #554 to see how our efforts in clinical, education, and research initiatives are setting new standards in digital solutions. *Research use only unless following CAP guidelines for LDT. CE-IVD certified for use in Europe.
Featured in G2 Intelligence January 2024—In an insightful discussion on the evolving landscape of data analytics within clinical laboratories, Lisa-Jean Clifford, COO and Chief Strategy Officer at Gestalt Diagnostics, highlights the integration of data analytics across various facets of laboratory operations. She emphasizes its critical role in enhancing operational efficiency, resource management, and patient safety. Clifford's commentary sheds light on the extensive applications of data analytics in lab environments—from streamlining operational workflows to improving patient care. She also addresses the challenges labs face, such as navigating the vast array of data analytics solutions and the need for specialized knowledge in pathology informatics. Moreover, Clifford points to the promising future of digital solutions and AI in expanding the capabilities of clinical labs, suggesting a burgeoning potential for growth and innovation in the field.
January 11, 2024 – Spokane, Washington – Gestalt announces the addition of Sagis Diagnostics to their customer roster. Recognizing the evolving landscape of healthcare technology, Sagis has embraced a transformative approach to their pathology services and has added digital pathology to their strategy. Gestalt’s industry leading, award-winning platform will be implemented for use in clinical and academic workflows, to include integrated artificial intelligence algorithms. By leveraging cutting-edge technology, Sagis aims to streamline the diagnostic process and enhance overall efficiency. The advantages of transitioning to digital pathology for the company include reducing operational costs and delays related to courier services and enabling real-time collaboration and access to patient cases for pathologists in various locations. “We believe that digital pathology is not just a technological upgrade but a strategic move towards a more sustainable and efficient future. By partnering with Gestalt, we aim to provide our pathologists with a state-of-the-art platform that aligns with our commitment to excellence," said Lynn Brock, COO at Sagis. “The thorough evaluation of various vendors led us to select Gestalt as the preferred partner. Through an exhaustive comparison of features, applications, and a detailed matrix analysis, Gestalt emerged as the vendor that best met our requirements, ticking off all the crucial aspects in clinical, research, and educational domains. This decision aligns with our commitment to staying at the forefront of technological advancements in healthcare.” The decision to embrace digital pathology was driven by several key factors. Initially, Sagis recognized significant cost-saving potential by eliminating the need for daily courier services to multiple cities in Texas, while also addressing challenges posed by weather conditions and unforeseen disruptions. Furthermore, Sagis sought to leverage Artificial Intelligence (AI) capabilities to empower pathologists and optimize diagnostic processes. The integration of AI allows for the pre-screening of specimens before pathologists begin their workday, ensuring a prioritized and efficient diagnostic workflow. A crucial aspect of this shift is the ability to attract and retain pathologists in an ever-shrinking pool of talent. The flexibility offered by digital pathology allows pathologists to work remotely, eliminating the need for relocation. This not only addresses the current challenges in hiring pathologists but also positions Sagis as an innovative and attractive employer in the healthcare sector. Gestalt COO & Chief Strategy Officer, Lisa-Jean Clifford says, “This shift represents a significant milestone in Sagis's commitment to delivering high-quality pathology services while embracing the opportunities presented by digital innovation. We are proud to work with innovative laboratories like Sagis who have a broad vision for expansion and use of technology and the positive impact this transition will have on patient care, as well as the broader healthcare ecosystem.” About Sagis Sagis is an entirely physician-led pathology group backed by a CLIA and CAP-accredited histology lab located in the heart of Houston, Texas. With board-certified and subspecialty-trained pathologists always within reach, we deliver the highest quality services to physicians, physician groups, ambulatory surgery centers, and hospitals. Our commitment to quality and excellence is built upon our expertise and the utilization of the latest diagnostic tools. Providing accurate, prompt, and clear diagnoses in a personal and customizable manner, we prioritize our referring physicians' needs. As a patient-centric facility, we strive to deliver the best medical care possible. Visit Sagis at www.sagisdx.com *Research use only unless following CAP guidelines for LDT. CE-IVD certified for use in Europe.
This award is another validation of Gestalt's contributions to supporting better healthcare through technology.
Featured in CAP TODAY December 2023—Digital pathology and AI—the push, the potential, the changing questions, the reimbursement, and the caution. All that and more came up when CAP TODAY publisher Bob McGonnagle led a conversation online with pathologists and industry representatives, featuring Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt.
With the advancement and expanded uses of technology in the laboratory we have a host of opportunities in the hands of physicians and scientists to explore and study diseases in-depth and in a way that we historically have not been able to. Read on to discover more...
